As of October 23, 2020, we are joining Gilead to advance our shared mission in developing breakthrough therapies for people living with cancer.
Learn more by visiting www.gilead.com. Read the press release.
Our Science
We are driven to boldly develop and deliver breakthrough therapies for cancer.
Learn MoreTechnologies and Platforms
A game-changing antibody-drug conjugate (ADC) platform that directs potent toxins to the tumor and tumor micro-environment to improve effectiveness and tolerability
Learn MoreCareers
Join a team committed to excellence and innovation — dedicated to developing the next generation of cancer therapies
Learn MorePatients
" data-parallax="scroll" class="parallax-bg" data-speed=".9">“Every day is precious. I treasure every opportunity to choose life, and have more time in the world with the people I love.”
Learn MoreOur Company
We take on some of the toughest challenges facing medical science today. We are a leader in next-generation antibody-drug conjugate technology, committed to help transform the lives of people with cancer.
Learn More
Latest
Immunomedics Announces FDA Orphan Drug Designation of Trodelvyᵀᴹ for Glioblastoma
Learn More
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvyᵀᴹ in Metastatic Urothelial Cancer
Learn More
Trodelvyᵀᴹ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
Learn More
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
Learn More
“The FDA approval of our first ADC therapy is our most prominent example of how we are delivering on our mission for all stakeholders: the triple-negative breast cancer (TNBC) community, our employees at Immunomedics, our stockholders, and our business partners and stakeholders.”